"Advancements in Cancer Research: Progress and Promise
P3 | N=300 | CAPItello-292 (NCT04862663) | Sponsor: AstraZeneca | "Positive high-level results from the CAPItello-291 Phase III trial...demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo plus Faslodex in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer, following recurrence or progression on or after endocrine therapy (with or without a CDK4/6 inhibitor). The trial met both primary endpoints, improving PFS in the overall patient population and in a prespecified biomarker subgroup of patients whose tumours had qualifying alterations in the PIK3CA, AKT1 or PTEN genes....The trial will continue to assess OS as a key secondary endpoint....The data will be presented at a forthcoming medical meeting and shared with global health authorities."